Otsuka Holdings Co., Ltd.: Schizophrenia trials

The registry lists 116 Schizophrenia studies with Otsuka Holdings Co., Ltd. as lead sponsor. 2 are open to participants now and 61 have results posted.

Phase 1 35Phase 2 14Phase 3 51Phase 4 12No phase 9(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male AdultsNot yet recruitingNCT07455084Phase 1
• A Long-term Administration Trial of SEP-363856 in Patients With SchizophreniaRecruitingNCT07225712Phase 3
• A Trial to Assess a Wearable Patch's Functioning to Detect Medication IngestionCompletedNCT06372210Not applicableResults posted
• Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With SchizophreniaCompletedNCT06036108Phase 1Results posted
• An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic MedicationCompletedNCT05741528Phase 3Results posted
• A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic MedicationCompletedNCT05628103Phase 3Results posted
• A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral DosesCompletedNCT04118127Phase 1Results posted
• A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.CompletedNCT04115319Phase 3Results posted
• A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaCompletedNCT04092686Phase 3Results posted
• A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaCompletedNCT04072354Phase 3Results posted
• A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) ImagingCompletedNCT04038957Phase 1Results posted
• A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 DisorderCompletedNCT04030143Phase 1/2Results posted
• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of SchizophreniaTerminatedNCT03896945Phase 2/3Results posted
• A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®TerminatedNCT03892889Phase 3Results posted
• A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive DisorderTerminatedNCT03643159Phase 4Results posted
• A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical AntipsychoticCompletedNCT03568500Phase 4Results posted
• Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With SchizophreniaCompletedNCT03238326Phase 3Results posted
• Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With SchizophreniaCompletedNCT03198078Phase 3Results posted
• An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With SchizophreniaCompletedNCT02970929Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With SchizophreniaCompletedNCT02969382Phase 2Results posted
• Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine SystemCompletedNCT02722967Phase 2Results posted
• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual SchizophreniaCompletedNCT02477670Phase 2Results posted
• A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic SchizophreniaTerminatedNCT02435836Phase 3Results posted
• A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With SchizophreniaCompletedNCT02220712Phase 1Results posted
• Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral AripiprazoleCompletedNCT02219009Phase 2Results posted
• Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With ImpulsivityCompletedNCT02194933Phase 3Results posted
• Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute SchizophreniaCompletedNCT02054702Phase 3Results posted
• Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode SchizophreniaCompletedNCT02013622Phase 3Results posted
• A Short Treatment Study of Aripiprazole in Pediatric Patients With SchizophreniaCompletedNCT01942161Phase 2/3Results posted
• A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With SchizophreniaCompletedNCT01942148Phase 3Results posted
• Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With SchizophreniaCompletedNCT01909466Phase 1Results posted
• A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM DepotCompletedNCT01870999Phase 1Results posted
• PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With SchizophreniaCompletedNCT01854944Phase 1Results posted
• Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With SchizophreniaCompletedNCT01683058Phase 3Results posted
• Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With SchizophreniaCompletedNCT01668797Phase 3Results posted
• Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With SchizophreniaCompletedNCT01663532Phase 3Results posted
• Multicenter, Open-label, Safety and Tolerability StudyCompletedNCT01649557Phase 2Results posted
• An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With SchizophreniaCompletedNCT01646827Phase 1Results posted
• Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than AripiprazoleCompletedNCT01552772Phase 1Results posted
• Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot AripiprazoleTerminatedNCT01509053Phase 3Results posted
• A Long-term Trial of OPC-34712 in Patients With SchizophreniaCompletedNCT01456897Phase 3Results posted
• A Dose-finding Trial of OPC-34712 in Patients With SchizophreniaCompletedNCT01451164Phase 2/3Results posted
• Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot AripiprazoleCompletedNCT01432444Phase 3Results posted
• Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective DisorderCompletedNCT01423916Phase 1Results posted
• Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With SchizophreniaCompletedNCT01397786Phase 3Results posted
• Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute SchizophreniaCompletedNCT01396421Phase 3Results posted
• Efficacy Study of OPC-34712 in Adults With Acute SchizophreniaCompletedNCT01393613Phase 3Results posted
• A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired SubjectsCompletedNCT01299454Phase 1Results posted
• Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired SubjectsCompletedNCT01289080Phase 1Results posted
• Efficacy & Safety Study of Oral Aripiprazole in Adolescents With SchizophreniaCompletedNCT01149655Phase 3Results posted
• An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With SchizophreniaCompletedNCT01129882Phase 3Results posted
• Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.TerminatedNCT01122927Phase 3Results posted
• Oral Aripiprazole Open-Label Rollover StudyCompletedNCT01001702Phase 3Results posted
• Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute SchizophreniaCompletedNCT00905307Phase 2Results posted
• Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic SyndromeTerminatedNCT00857818Phase 3Results posted
• Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With SchizophreniaCompletedNCT00731549Phase 3Results posted
• Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With SchizophreniaCompletedNCT00706654Phase 3Results posted
• Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With SchizophreniaCompletedNCT00705783Phase 3Results posted
• Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-CompletedNCT00392197Phase 4Results posted
• Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical TrialsCompletedNCT00239356Phase 3Results posted
• Aripiprazole Open-Label, Safety and Tolerability StudyCompletedNCT00102518Phase 3Results posted
• Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and AdolescentsCompletedNCT00102479Phase 1Results posted
• Aripiprazole in Adolescents With SchizophreniaCompletedNCT00102063Phase 3Results posted
• A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive EpisodeCompletedNCT07549581Phase 1
• A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and WomenCompletedNCT07305779Phase 1
• A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaActive, not recruitingNCT06894212Phase 3
• A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With SchizophreniaCompletedNCT05848700Phase 1
• A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With SchizophreniaCompletedNCT05542264Phase 1
• A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With SchizophreniaCompletedNCT05463770Phase 1
• A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) StandardCompletedNCT05402111Phase 1
• A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With SchizophreniaCompletedNCT05326347Phase 3
• A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With SchizophreniaWithdrawnNCT05119894Phase 1
• Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)Status unknownNCT04907279
• A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.CompletedNCT04865835Phase 1
• "Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"Status unknownNCT04641780
• A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.CompletedNCT04369391Phase 1
• A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With SchizophreniaTerminatedNCT04109950Phase 3
• Safety and Efficacy of Brexpiprazole in the Treatment of SchizophreniaCompletedNCT03874494Phase 3
• Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar DisorderCompletedNCT03872596Phase 1
• A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I DisorderCompletedNCT03854409Phase 1
• Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 DisorderCompletedNCT03386851
• MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical AntipsychoticsCompletedNCT03376763Phase 4
• Aripiprazole IM Depot for Chinese Patients With SchizophreniaCompletedNCT03287505Phase 1
• PK Study of Aripiprazole IM Depot for Chinese Patients With SchizophreniaCompletedNCT03285503Phase 1
• Aripiprazole IM Depot in the Acute Treatment of Adults With SchizophreniaCompletedNCT03172871Phase 3
• Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With SchizophreniaCompletedNCT03150771Phase 1
• Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in SpainCompletedNCT03130478
• Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset SchizophreniaStatus unknownNCT03130465
• Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in ItalyCompletedNCT03005769
• Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With SchizophreniaTerminatedNCT02968121Phase 1
• Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With SchizophreniaCompletedNCT02411695Phase 1
• Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or SchizophreniaCompletedNCT02050854
• Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With SchizophreniaCompletedNCT01994473Phase 1
• Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I DisorderWithdrawnNCT01981811Phase 2
• Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype CharacteristicsCompletedNCT01972711Phase 1
• A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With SchizophreniaCompletedNCT01940159Phase 1
• Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712CompletedNCT00805454Phase 1
• Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute SchizophreniaCompletedNCT00712686Phase 3
• Health Evaluation of Abilify Long-term TherapyCompletedNCT00520650Phase 4
• Effect on Cognitive Function of a Treatment With AripiprazoleCompletedNCT00329810Phase 4